As much of the world struggles with a burgeoning second wave of Coronavirus cases, ASX-listed bio-pharma company MGC Pharmaceuticals is surging forward with an expanded Phase 2 Clinical Trial of its “ArtemiC” natural supplement. In early stage testing the drug has shown promising signs of its effectiveness in treating COVID-19 and MGC Pharma is moving quickly through the gears in its assessment of the drug’s ability to fight the virus.
MGC Pharma has added a third hospital in Israel to its Phase 2 trial of the ArtemiC anti-inflammatory formulation after interim results of the trial met all the primary endpoints for the safety and efficacy of the treatment on the first 10 patients.
According to MGC Pharma, interim results from its trial in Israel showed significant improvement in the patients, with no adverse events or pain suffered and no intensive care or ventilation required.
The company said 3 patients were already enrolled for the Phase 2 Clinical Trial on COVID-19 patients at the leading Rambam Academic Hospital in Israel, adding to the patients already recruited at the Nazareth Hospital EMMS and Hillel Yaffe Hospital back in May 2020.
MGC said ArtemiC is a natural food supplement formulation based on Artemisinin and Curcumin mixed with supporting ingredients, Vitamin C and Boswellia serrata, both of which are well-known natural active ingredients with anti-infective properties.
According to MGC Pharma, pre-clinical, in-vitro lab test results supported the claim ArtemiC can modify the function of human immune cells in response to inflammatory stimuli. Some elements of the formulation demonstrate an effective response on immune function in a manner considered desirable in combating the virus.
Read the article by Matt Birney in The West Australian.